First Horizon Advisors Inc. Grows Stock Holdings in Johnson & Johnson (NYSE:JNJ)

First Horizon Advisors Inc. boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 259,166 shares of the company's stock after buying an additional 10,322 shares during the period. Johnson & Johnson makes up about 1.2% of First Horizon Advisors Inc.'s holdings, making the stock its 15th largest holding. First Horizon Advisors Inc.'s holdings in Johnson & Johnson were worth $42,001,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in JNJ. Price T Rowe Associates Inc. MD lifted its stake in Johnson & Johnson by 16.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 21,834,359 shares of the company's stock worth $3,453,978,000 after purchasing an additional 3,139,499 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Johnson & Johnson by 10.8% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 18,780,645 shares of the company's stock valued at $2,744,979,000 after purchasing an additional 1,831,751 shares during the period. Ameriprise Financial Inc. increased its holdings in Johnson & Johnson by 5.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 14,374,397 shares of the company's stock valued at $2,100,427,000 after purchasing an additional 754,200 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Johnson & Johnson by 16.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 13,147,352 shares of the company's stock worth $1,921,565,000 after acquiring an additional 1,829,257 shares during the period. Finally, American Century Companies Inc. grew its holdings in shares of Johnson & Johnson by 5.8% during the 2nd quarter. American Century Companies Inc. now owns 8,014,213 shares of the company's stock worth $1,171,357,000 after acquiring an additional 437,637 shares during the period. Institutional investors own 69.55% of the company's stock.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the firm's stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares of the company's stock, valued at approximately $3,131,683.38. This trade represents a 22.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Wells Fargo & Company upped their target price on Johnson & Johnson from $163.00 to $166.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 16th. Guggenheim upped their price target on Johnson & Johnson from $156.00 to $162.00 and gave the stock a "neutral" rating in a research note on Wednesday, November 6th. Daiwa America downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 23rd. Wolfe Research began coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an "outperform" rating and a $190.00 price target on the stock. Finally, StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, September 14th. Seven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus target price of $175.94.

Johnson & Johnson Stock Performance

NYSE JNJ traded up $0.09 on Wednesday, reaching $153.10. 9,060,825 shares of the company's stock traded hands, compared to its average volume of 7,028,536. The stock has a 50 day moving average price of $160.83 and a 200-day moving average price of $156.19. The firm has a market cap of $368.59 billion, a price-to-earnings ratio of 22.09, a P/E/G ratio of 2.74 and a beta of 0.53. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. During the same period in the previous year, the business posted $2.66 EPS. Johnson & Johnson's revenue was up 5.2% on a year-over-year basis. Equities research analysts predict that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.24%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson's dividend payout ratio is presently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.